WO2024075080 - NEODEGRADER CONJUGATES
National phase entry:
Publication Number
WO/2024/075080
Publication Date
11.04.2024
International Application No.
PCT/IB2023/060064
International Filing Date
06.10.2023
Title **
[English]
NEODEGRADER CONJUGATES
[French]
CONJUGUÉS DE NÉO-DÉGRADATEURS
Applicants **
ORUM THERAPEUTICS, INC.
Inventors
FISHKIN, Nathan
KIM, Min-Soo
TAKROURI, Khuloud
PALACINO, James
CHOI, Dong-Ki
KIM, Da-Yeong
JEONG, Hangyeol
Priority Data
63/378,663
06.10.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4130 | |
| EPO | Filing, Examination, Granting | 52134 | |
| Japan | Filing, Examination, Granting | 3755 | |
| South Korea | Filing, Examination, Granting | 3752 | |
| USA | Filing, Examination, Granting | 15590 |
Total:
79,361
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides neoDegraders conjugated to binding moieties that specifically bind to CD56. Also provided are compositions comprising the neoDegrader conjugates. The compounds and compositions are useful for treating a disease or condition, e.g., cancer, in a subject in need thereof.[French]
La présente divulgation concerne des néo-dégradateurs (neoDegraders) conjugués à des fractions de liaison qui se lient spécifiquement à CD56. L'invention concerne également des compositions comprenant les conjugués neoDegraders. Les composés et les compositions sont utiles pour traiter une maladie ou un état pathologique, par exemple, un cancer, chez un sujet en ayant besoin.